CanSino Biologics (HKSE:06185) Debt-to-Equity : 0.43 (As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is CanSino Biologics Debt-to-Equity?

CanSino Biologics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$1,285.7 Mil. CanSino Biologics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$1,079.7 Mil. CanSino Biologics's Total Stockholders Equity for the quarter that ended in Jun. 2024 was HK$5,446.8 Mil. CanSino Biologics's debt to equity for the quarter that ended in Jun. 2024 was 0.43.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for CanSino Biologics's Debt-to-Equity or its related term are showing as below:

HKSE:06185' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.29 Max: 0.51
Current: 0.43

During the past 8 years, the highest Debt-to-Equity Ratio of CanSino Biologics was 0.51. The lowest was 0.02. And the median was 0.29.

HKSE:06185's Debt-to-Equity is ranked worse than
62.47% of 826 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs HKSE:06185: 0.43

CanSino Biologics Debt-to-Equity Historical Data

The historical data trend for CanSino Biologics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanSino Biologics Debt-to-Equity Chart

CanSino Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.11

0.02

0.17

0.40

0.51

CanSino Biologics Quarterly Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Debt-to-Equity	Get a 7-Day Free Trial														0.41	0.34	0.51	0.42	0.43

Competitive Comparison of CanSino Biologics's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CanSino Biologics's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where CanSino Biologics's Debt-to-Equity falls into.

CanSino Biologics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

CanSino Biologics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1596.368	+	1357.208)	/	5769.25
	=	0.51

CanSino Biologics's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1285.658	+	1079.688)	/	5446.821
	=	0.43

CanSino Biologics (HKSE:06185) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

CanSino Biologics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of CanSino Biologics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

CanSino Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (HKSE:06185) » Definitions » Debt-to-Equity

Traded in Other Exchanges

CASBF:USA CJH:Germany 688185:China

Address

185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN

Website

https://www.cansinotech.com

CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. Its products are Menhycia and Menphecia; Convidecia, Convidecia Air, and XBB.1.5 Variant; Ad5-EBOV; PCV13i; PBPV; and DTcP Infant. Its geographic areas are PRC and Overseas. It generates the majority of its revenue from the PRC.

Executives

The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.
Citigroup Inc.
The Goldman Sachs Group, Inc.	2201 Interest of corporation controlled by you
Blackrock, Inc.	2201 Interest of corporation controlled by you
Mao Helen Huihua	2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd.	2201 Interest of corporation controlled by you
Qiming Gp Iv, L.p.	2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p.	2201 Interest of corporation controlled by you
Qm29 Limited	2101 Beneficial owner
Qiu Dongxu	2501 Other
Yu Xuefeng	2501 Other
Zhu Tao
Chao Shou Bai	2202 Interest of your spouse
Orbimed Capital Llc	2102 Investment manager

CanSino Biologics Headlines

No Headlines